PMID: 9529075Apr 7, 1998Paper

Enhanced protective antibody responses to PspA after intranasal or subcutaneous injections of PspA genetically fused to granulocyte-macrophage colony-stimulating factor or interleukin-2

Infection and Immunity
C WorthamJ J Mond

Abstract

Antibody to pneumococcal surface protein A (PspA) has been shown to be protective for Streptococcus pneumoniae infections in mice. In an attempt to define a model for inducing protective antibody to PspA in the absence of adjuvant, we designed two genetic fusions, PspA-interleukin-2 [IL-2]) and PspA-granulocyte-macrophage colony-stimulating factor (GM-CSF). These constructs maintained high cytokine function in vitro, as tested by their activity on IL-2 or GM-CSF-dependent cell lines. While intranasal immunization with PspA induced no detectable anti-PspA response, both PspA-IL-2 and PspA-GM-CSF stimulated high immunoglobulin G1 (IgG1) antibody responses. Interestingly, only the PspA-IL-2, not the PspA-GM-CSF, construct stimulated IgG2a antibody responses, suggesting that this construct directed the response along a TH1-dependent pathway. Comparable enhancement of the anti-PspA response with similar isotype profiles was observed after subcutaneous immunization as well. The enhancement observed with PspA-IL-2 was dependent on IL-2 activity in that it was not seen in IL-2 receptor knockout mice, while PspA in alum induced high-titer antibody in these mice. The antibody was tested for its protective activity in a mouse lethality mo...Continue Reading

References

Jan 1, 1995·Annual Review of Immunology·J J MondC M Snapper
May 1, 1994·Journal of Bacteriology·J Yother, J M White
Mar 1, 1996·Immunology Today·T R Mosmann, S Sad
Oct 25, 1996·Annals of the New York Academy of Sciences·D E BrilesL S McDaniel
Jan 1, 1997·Annual Review of Immunology·S L Constant, K Bottomly

❮ Previous
Next ❯

Citations

Dec 20, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·Z Q WuC M Snapper
Jan 30, 2013·Human Vaccines & Immunotherapeutics·Mark D Mannie, Alan D Curtis
Apr 23, 2015·Human Vaccines & Immunotherapeutics·Muna F AbryBenard W Kulohoma
May 11, 2002·Critical Reviews in Microbiology·Lucia H LeeCarl E Frasch
May 22, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Deirdre Thomas-RudolphCarolyn Mold
May 23, 2000·The Pediatric Infectious Disease Journal·J Eskola, T Kilpi
Sep 23, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jesus Colino, Clifford M Snapper
Feb 22, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Mark D MannieDerek J Abbott
Aug 6, 2003·FEMS Immunology and Medical Microbiology·Edwin Swiatlo, Daphne Ware
Feb 13, 2001·Molecular Immunology·G S BuchanM A Baird
May 20, 2004·Vaccine·D BogaertR de Groot

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.